{"url_path":"/sec/rckt/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-026982-index.html","accession_number":"0001140361-26-026982","cik":"0001281895","ticker":"RCKT","issuer_name":"ROCKET PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-026982-index.html","primary_entity_key":"0001281895","primary_entity_name":"ROCKET PHARMACEUTICALS, INC."},"word_count":331,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the “Company” or “Rocket”) of his resignation as VP of Finance, Senior Controller,\nTreasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities.\n\nOn June 30, 2026, Joseph Manhede, the Company’s Associate Vice President, Corporate Controller, was appointed as the Company’s Principal Accounting\nOfficer, effective July 8, 2026.\n\nMr. Manhede, age 48, has served as the Company’s Associate Vice President, Corporate Controller since April 2026.  Prior to Rocket, Mr. Manhede was the\nVice President and Financial Controller for Outlook Therapeutics, a clinical-stage biopharmaceutical company, where he was responsible for leading accounting and finance functions, including financial reporting, SEC compliance, internal controls,\nbudgeting, and strategic financial planning, as well as supporting financing transactions and corporate governance initiatives.  Prior to his time at Outlook, Mr. Manhede held senior finance and accounting positions at Amneal Pharmaceuticals,\nUnilife Corporation, and Celator Pharmaceuticals, Inc., where he served as Corporate Controller and played a key role in financial reporting, IPO readiness, SOX compliance, and acquisition integration. He began his career at Deloitte, where he\nserved as an Audit Manager. Mr. Manhede is a Certified Public Accountant (CPA) and holds a Master of Business Administration from Holy Family University.\n\nNo new compensatory arrangements will be entered into with Mr. Manhede in connection with his designation as the Company’s Principal Accounting Officer.\nThere are no family relationships between Mr. Manhede and any other director or executive officer of the Company, and no transactions involving Mr. Manhede that would require disclosure under Item 404(a) of Regulation S-K.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned hereunto duly authorized.\n\n \n\nRocket Pharmaceuticals, Inc.\n\n \n\n \n\n \n\nDate: June 30, 2026\n\nBy:\n\n/s/ Martin Wilson\n\n \n\n \n\nMartin Wilson\n\n \n\n \n\nGeneral Counsel and Chief Corporate Officer"}